-
May 18, 2026Interim Phase 2 Data for Hexavalent OX40 Agonist Combination Therapy in First-Line HNSCC Demonstrate Potential Benefit Over PD-1 Monotherapy
Elpiscience's partner Inhibrx recently announced positive interim Phase 2 results for INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab as a first-line treatment for head and
-
May 11, 2026Elpiscience Announces First Patient Dosed in Phase II Trial of ES014 for Desmoid Tumors
Elpiscience announced that the first patient has been successfully dosed in the Phase II clinical trial of its independently developed first-in-class CD39/TGF-β bispecific antibody, ES014, f
-
March 20, 2026AACR 2026 Preview | Elpiscience's FIC CD39/TGF-β BsAb ES014 Selected for Poster Presentation
The independently developed, first-in-class CD39/TGF-β bispecific antibody(bsAb) of Elpiscience, ES014, has been selected for poster presentation at the 2026 AACR. The latest research findings wi
-
March 04, 2026Elpiscience’s Independently Developed BsAb ES014 Receives FDA Orphan Drug Designation, Accelerating Global Development in Desmoid Tumors
- ES014 demonstrated encouraging single-agent activity in the Phase I study, achieving an objective response rate (ORR) of 40% and disease control rate (DCR) of 100% in patients wit...
-
December 05, 2025Elpiscience Presents Phase I Data for First-in-Class ES014 (CD39/TGF-β Bispecific Antibody) in Oral Session at ESMO Asia
On December 5, 2025, Elpiscience, a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies, presented phase I clinical trial results for its internally developed b...
-
November 28, 2025Preview | Oral Presentation at ESMO Asia 2025: First-in-Human Results of ES014, the World’s First CD39/TGF-β Bispecific Antibody, as Monotherapy in Advanced Solid Tumors to Be Unveiled
Elpiscience announced that the first-in-human Phase I clinical results of ES014, the world’s first-in-class CD39/TGF-β bispecific antibody developed in-house, will be presented as an oral p...